γ-Hydroxybutyric acid
| Clinical data | |
|---|---|
| Other names | GHB, γ-hydroxybutyrate, oxybate |
| Addiction liability | High |
| Routes of administration | By mouth, intravenous |
| Drug class | GHB receptor agonist; GABAB receptor agonist; Depressant; Hypnotic; Sedative |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 25% (oral) |
| Metabolism | 95–98%, mainly liver, also in blood and tissues |
| Metabolites | Succinic semialdehyde, Succinic acid |
| Onset of action | Within 5–15 minutes |
| Elimination half-life | 30–60 minutes |
| Excretion | 1–5%, kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.218.519 |
| Chemical and physical data | |
| Formula | C4H8O3 |
| Molar mass | 104.105 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
γ-Hydroxybutyric acid (GHB), also known as 4-hydroxybutanoic acid, is a naturally occurring neurotransmitter and a depressant drug. It is a precursor to GABA, glutamate, and glycine in certain brain areas. It acts on the GHB receptor and is a weak agonist at the GABAB receptor. GHB has been used in medicine as a general anesthetic and as treatment for cataplexy, narcolepsy, and alcohol use disorder. It is also used illicitly for performance enhancement, date rape, and recreation.
It is commonly used in the form of a salt, with the conjugate base of GHB being called γ-hydroxybutyrate or oxybate. The sodium (NaGHB, sodium oxybate, or Xyrem) and potassium (KGHB, potassium oxybate) salts are common. GHB is produced as a result of fermentation, and is found in small quantities in some beers and wines, beef, and small citrus fruits.
Succinic semialdehyde dehydrogenase deficiency causes GHB to accumulate in the blood.